Vitamin D [25(OH)D] metabolites and epimers in obese subject: Interaction and correlations with adverse metabolic health risk factors.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

The researchers aimed to assess the role of vitamin D metabolites as potential mediators in the association between obesity, inflammation and metabolic risk factors.

Why It Was Studied

Although both vitamin D deficiency and obesity are highly prevalent in the UAE, the role of vitamin D metabolites in mediating obesity-related adverse health effects is not clear.

Who Took Part

The abstract describes 277 participants taking part.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

277 participants who were part of a randomized controlled trial had their assessment that included clinical, anthropometric and physical activity data at baseline and at 6 months.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

What Was Measured

Topics PubMed links to this paper include 25-Hydroxyvitamin D 2, Body Mass Index, Calcifediol, Calcitriol, Diabetes Mellitus, Type 2, Glycated Hemoglobin and Multivariate Analysis.

Author keywords: 25(OH) D, Epimers, Inflammation, Metabolic risk factors and Obesity.

What This Means in Plain Language

The paper is a randomized study of Vitamin D, K2, Magnesium and Zinc in 277 participants.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (The Journal of steroid biochemistry and molecular biology), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.